Literature DB >> 1351434

Antineutrophil cytoplasmic antibody (cANCA and pANCA) titers in relation to disease activity in patients with necrotizing vasculitis: a longitudinal study.

E Pettersson1, Z Heigl.   

Abstract

The significance of the antineutrophil cytoplasmic antibodies, cANCA or pANCA, in relation to disease activity in various types of necrotizing vasculitis was assessed in a longitudinal study. Twenty patients, 14 cANCA positive and 6 pANCA positive were followed for up to seven years. Eleven of the 14 cANCA positive and two out of the 6 pANCA positive patients had Wegener's granulomatosis, two other cANCA patient and one pANCA patient had systemic vasculitis, whereas one cANCA and three pANCA positive patients had disease limited to the kidneys. Disease activity was expressed as a numerical index DAI, based on extent and type of organ involvement (DAI greater than or equal to 5 = active disease). At the time of disease debut the DAI ranged between 11 and 32, cANCA titers between 18 and greater than 1000 U/l, and pANCA titers between 51 and 630 U/l in individual patients. With clinical recovery both c- and pANCA titers declined. Clinical remission (DAI less than 5) occurred within a mean of 2.5 months (range 1 to 4). Almost simultaneously cANCA titers turned negative (less than 10 U/l), although one patient remained positive for seven years. pANCA titers remained positive for long periods of time in 5/6 patients. Five cANCA patients had clinical exacerbations, which in two patients were preceded by seroconversions from - to +, lasting 3 and 12 months before the clinical relapse. One additional cANCA patient had two serological relapses without signs of clinical activity during a 2-year follow-up. In conclusion, we saw a close correlation between DAI and cANCA titers in individual patients: with decreasing clinical activity (DAI), the cANCA titers decrease. Interindividual variation is great; despite a high DAI, the cANCA titers may be relatively low. Serological relapses may indicate forthcoming clinical relapses. Relapses may develop as late as 5-6 years after onset. pANCA titers, on the other hand, tend to remain positive for long periods, despite clinical remission.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1351434

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  13 in total

1.  Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis.

Authors:  Gunnar Tomasson; Peter C Grayson; Alfred D Mahr; Michael Lavalley; Peter A Merkel
Journal:  Rheumatology (Oxford)       Date:  2011-10-29       Impact factor: 7.580

Review 2.  Risk factors for treatment failures in antineutrophil cytoplasmic antibody- associated small-vessel vasculitis.

Authors:  Vijay R Karia; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2009-12       Impact factor: 4.592

Review 3.  ANCA testing. New developments and clinical implications.

Authors:  A E Ahmed; J B Peter; Y Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 4.  Assessment of disease activity in systemic vasculitis.

Authors:  W Y Tse; P Cockwell; C O Savage
Journal:  Postgrad Med J       Date:  1998-01       Impact factor: 2.401

5.  Wegener's granulomatosis with a possible thyroidal involvement.

Authors:  Hakan Ozdogu; Can Boga; Filiz Bolat; Melek Eda Ertorer
Journal:  J Natl Med Assoc       Date:  2006-06       Impact factor: 1.798

6.  Anti-idiotypic activity against anti-myeloperoxidase antibodies in pooled human immunoglobulin.

Authors:  A A Pall; M Varagunam; D Adu; N Smith; N T Richards; C M Taylor; J Michael
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

Review 7.  Mechanisms of endothelial cell injury in vasculitis.

Authors:  A A Pall; C O Savage
Journal:  Springer Semin Immunopathol       Date:  1994

8.  Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis.

Authors:  Mårten Segelmark; Brian D Phillips; Susan L Hogan; Ronald J Falk; J Charles Jennette
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

9.  Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.

Authors:  Lynn A Fussner; Amber M Hummel; Darrell R Schroeder; Francisco Silva; Rodrigo Cartin-Ceba; Melissa R Snyder; Gary S Hoffman; Cees G M Kallenberg; Carol A Langford; Peter A Merkel; Paul A Monach; Philip Seo; Robert F Spiera; E William St Clair; Nadia K Tchao; John H Stone; Ulrich Specks
Journal:  Arthritis Rheumatol       Date:  2016-07       Impact factor: 10.995

10.  Relation between asymptomatic proteinase 3 antibodies and future granulomatosis with polyangiitis.

Authors:  Stephen W Olson; David Owshalimpur; Christina M Yuan; Charles Arbogast; Thomas P Baker; David Oliver; Kevin C Abbott
Journal:  Clin J Am Soc Nephrol       Date:  2013-05-02       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.